Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) -- The "Non-Infectious Macular Edema Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The global market for Non-Infectious Macular Edema Treatment was estimated at US$17.1 Billion in 2023 and is projected to reach US$25.0 Billion by 2030, growing at a CAGR of 5.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. 
Early and effective treatment is crucial for maintaining quality of life, especially for patients with underlying chronic conditions like diabetes. The treatment landscape has advanced significantly with the introduction of anti-VEGF therapies, which specifically target the abnormal blood vessels that contribute to fluid leakage and macular swelling, offering patients better outcomes and fewer side effects than traditional treatments.
What Are the Key Growth Drivers in the Non-Infectious Macular Edema Treatment Market?
The growth in the non-infectious macular edema treatment market is driven by several key factors, starting with the rising prevalence of diabetes and associated retinal complications like diabetic macular edema. As more people are diagnosed with diabetes worldwide, the need for effective treatments for macular edema is increasing. Another critical driver is the widespread adoption of anti-VEGF therapies, which have significantly improved outcomes for patients with macular edema by reducing fluid accumulation and improving vision.
Technological advancements in drug delivery systems, such as sustained-release implants, are also fueling market growth by providing longer-lasting treatments and reducing the burden of frequent injections. Additionally, the aging population is contributing to the demand for macular edema therapies, as age-related eye conditions become more common. The increasing focus on early diagnosis and treatment, supported by advanced imaging techniques like optical coherence tomography (OCT), is further driving market expansion by enabling more precise and effective treatment strategies.
How Is the Non-Infectious Macular Edema Treatment Market Evolving?
The non-infectious macular edema treatment market is evolving with the increasing availability of targeted biologic therapies such as anti-VEGF injections, which have become the standard of care for many patients. One key trend is the growing use of these biologics, including ranibizumab and aflibercept, which are designed to inhibit the growth of abnormal blood vessels and reduce fluid leakage in the retina. These therapies are proving to be highly effective in improving vision and reducing the need for more invasive treatments, such as laser therapy or surgery.
Another significant trend is the development of long-acting corticosteroid implants and sustained-release drug delivery systems. These innovations reduce the frequency of treatments, offering patients more convenience and better adherence to their treatment regimens. Additionally, advancements in imaging technologies, such as optical coherence tomography (OCT), are improving the diagnosis and monitoring of macular edema, enabling more precise and individualized treatment approaches. As researchers continue to explore new therapies targeting inflammation and fluid accumulation, the market is expected to expand with more options for patients.
Which Patient Groups Are Driving the Demand for Macular Edema Treatment?
The demand for non-infectious macular edema treatments is largely driven by patients with underlying chronic conditions that increase the risk of macular edema, particularly individuals with diabetic retinopathy. As diabetes becomes more prevalent globally, the incidence of diabetic macular edema is rising, leading to higher demand for effective therapies. Similarly, patients with retinal vein occlusion (RVO), a condition that can cause fluid accumulation in the retina, are significant users of macular edema treatments.
Another key patient group includes individuals with uveitis, an inflammatory disease of the eye that can lead to macular edema. These patients often require corticosteroids or immunosuppressive therapies to manage inflammation and prevent vision loss. The aging population is also a key driver of demand, as older adults are more likely to experience macular edema due to age-related retinal conditions. Early diagnosis and timely treatment are critical for these patients to preserve vision and maintain independence.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Anti-VEGF Drug segment, which is expected to reach US$16.6 Billion by 2030 with a CAGR of a 5.3%. The Corticosteroids Drug segment is also set to grow at 6.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was valued at $4.6 Billion in 2023, and China, forecasted to grow at an impressive 5.2% CAGR to reach $3.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Alimera Sciences, Inc., Allergan PLC, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 196 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $17.1 Billion |
| Forecasted Market Value (USD) by 2030 | $25 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Global Economic Update
- Non-Infectious Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
MARKET TRENDS & DRIVERS
- Rising Prevalence of Non-Infectious Macular Edema (NIME) Fuels Demand for Advanced Treatment Solutions
- Increasing Adoption of Anti-VEGF Therapies Expands Market for Effective Non-Infectious Macular Edema Treatments
- Growing Use of Corticosteroid Implants Strengthens Market for Long-Term Control of Non-Infectious Macular Edema
- Technological Advancements in Ophthalmic Drug Delivery Propel Growth in Sustained-Release Treatment Options for NIME
- Rising Focus on Minimally Invasive Treatments Expands Opportunities for Intraocular Injections and Implants in NIME
- Growing Adoption of Combination Therapies in NIME Expands Market for Multi-Modal Treatment Approaches
- Increasing Focus on Retinal Imaging and Diagnostic Tools Fuels Growth in Early Detection and Monitoring of Non-Infectious Macular Edema
- Rising Use of Personalized Medicine and Genetic Testing Expands Opportunities for Targeted NIME Therapies
- Growing Use of Anti-Inflammatory Agents in Non-Infectious Macular Edema Expands Market for Corticosteroid and Immunosuppressant Therapies
- Increasing Focus on Drug-Resistant Non-Infectious Macular Edema Expands Market for Innovative Treatment Solutions
- Technological Developments in Nanotechnology Propel Growth in Non-Infectious Macular Edema Drug Delivery Systems
- Rising Demand for Biologics in Non-Infectious Macular Edema Treatment Strengthens Market for Advanced Therapeutics
FOCUS ON SELECT PLAYERS (Total 46 Featured)
- AbbVie, Inc.
- Alimera Sciences, Inc.
- Allergan PLC
- Amgen, Inc.
- Bausch Health Companies, Inc.
- Bayer AG
- Clearside Biomedical, Inc.
- F. Hoffmann-La Roche AG
- Novartis International AG
- Pfizer, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/n2t5hi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
